



CIN: L24200MH1989PLC051018

Registered Office: 5th Floor, A-Wing, Sun Magnetica, LIC Service Road, Louiswadi,
Thane (W) – 400604, Maharashtra, India

Email: info@advancedenzymes.com, **Website:** www.advancedenzymes.com

Tel.: +91-22-41703200; **Fax:** +91-22-25835159

NOTICE

NOTICE is hereby given that the **37th (Thirty-Seventh) Annual General Meeting ("AGM")** of the Members of **ADVANCED ENZYME TECHNOLOGIES LIMITED** will be held on **Friday, July 31, 2026 at 10:00 A.M. (IST)** through Video Conference ("VC") / Other Audio Visual Means ("OAVM"), to transact the following Business:

Ordinary Business:

1. To receive, consider and adopt the Audited Financial Statements (Standalone) of the Company for the financial year ended March 31, 2026 together with the Auditors' report thereon and the report of the Board of Directors of the Company; and the Audited Financial Statements (Consolidated) of the Company for the financial year ended March 31, 2026 together with the Auditors' report thereon.
2. To declare final Dividend (₹ 1.35/- per Equity Share) on the Equity Shares of ₹ 2/- each, for the financial year ended March 31, 2026.
3. To appoint a Director in place of Ms. Rasika Rathi (DIN: 08300682), who retires by rotation and being eligible, offers herself for re-appointment as a Director.
4. **To reappoint M/s. MSKA & Associates LLP (Firm Registration No. 105047W/W101187) (Formerly known as MSKA & Associates) as the Statutory Auditors of the Company and fix their remuneration**

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 139, 141, 142 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactments thereof for the time being in force) and based on the recommendations of the Audit Committee and the Board of Directors of the Company, approval of the Members be and is hereby accorded to reappoint M/s. MSKA & Associates LLP (Formerly known as MSKA & Associates), Chartered Accountants, (Firm Registration No. 105047W/W101187) as the Statutory Auditors of the Company for a second term of 5 (Five) consecutive years, from the conclusion of this 37th Annual General Meeting of the Company ("**AGM**") until the conclusion of 42nd AGM, at such remuneration plus applicable taxes and actual out of pocket expenses, if any, in connection with the Statutory Audit/Limited Review of the financial statements/

results and other certifications/scope of services, as may be mutually agreed and the Board of Directors of the Company may decide in this behalf.

RESOLVED FURTHER THAT the Board of Directors of the Company or any Committee thereof be and is hereby authorized to do all such acts, deeds and things as may be necessary to give effect to this resolution."

Special Business:

5. **Re-appointment of Mr. Mukund Madhusudan Kabra (DIN: 00148294) as a Whole-time Director of the Company**

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 152, 196, 197, 203, Schedule V and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactments thereof for the time being in force) and the Articles of Association of the Company and based on the recommendation of the Nomination and Remuneration Committee and Board of Directors of the Company, approval of the Members of the Company be and is hereby accorded for the re-appointment of Mr. Mukund Madhusudan Kabra (DIN: 00148294) as Whole-Time Director (Key Managerial Personnel) of the Company for term of 5 (Five) years with effect from April 01, 2027, liable to retire by rotation, as per the terms including the remuneration as mentioned in the Explanatory Statement.

RESOLVED FURTHER THAT the Board of Directors of the Company and / or any Committee thereof be and is hereby authorised to settle any question, difficulty or doubts that may arise and to do all such acts, deeds and things as may be necessary, usual, proper or expedient in this regard."

6. **Appointment of Mr. Pradip Bhailal Shah (DIN: 01225582) as an Independent Director of the Company**

To consider and if thought fit, to pass the following Resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 149, 150, 152 and Schedule IV of Companies Act, 2013, corresponding rules framed thereunder and such other provisions as may be applicable ("**Act**"),

read with the provisions of Regulation 17, 25 and other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the Explanatory Statement annexed to the Notice convening the 37th Annual General Meeting of the Company, and upon the recommendation of the Nomination and Remuneration Committee and the Board of Directors, approval of the Members of the Company be and is hereby accorded for the appointment of Mr. Pradip Bhailal Shah (DIN: 01225582), who was appointed as an Additional Director (Independent) with effect from June 12, 2026, as an Independent Director on the Board of the Company, not liable to retire by rotation, and to hold office for a period of 5 (Five) consecutive years from June 12, 2026 to June 11, 2031 and in respect of whom the Company has received a Notice in writing from a Member under Section 160 of the Act, signifying the intention of the said Member to propose the candidature of Mr. Pradip Bhailal Shah (DIN: 01225582) for the office of Director.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 149, 197, and other applicable provisions of the Act and the Rules made thereunder, Mr. Pradip Bhailal Shah shall be entitled to receive sitting fees and commission, as approved by the Board of Directors, from time to time.

RESOLVED FURTHER THAT the Board of Directors of the Company and / or any Committee thereof be and is hereby authorised to settle any question, difficulty or doubts that may arise and to do all such acts, deeds and things as may be necessary, usual, proper or expedient in this regard."

7. Approval for payment of the remuneration of Ms. Manasi Kabra (Immediate Relative of Whole Time Director) who holds Office or Place of Profit in the Subsidiary of the Company in USA

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 188(1)(f) and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 (**"Act"**) (including any statutory modification(s) or re-enactments thereof for the time being in force), and based upon the recommendation of the Audit Committee and the Board of Directors, approval of the Members of the Company be and is hereby accorded to continue to hold an office or place of profit by Ms. Manasi Kabra, an immediate relative of Whole-time Director of the Company, in Cal-India Foods International, a step-down wholly owned subsidiary in USA, and to pay her the monthly remuneration not exceeding such sum as mentioned

in the Explanatory Statement, with liberty to the Board of Directors (including the Committees of the Board) to vary, amend or revise the remuneration and the terms and conditions of her office in accordance with the provisions of the Act, as may be agreed to between the Board of Directors and Ms. Manasi Kabra.

RESOLVED FURTHER THAT the Board of Directors of the Company and / or any Committee thereof be and is hereby authorised to settle any question, difficulty or doubts that may arise and to do all such acts, deeds and things as may be necessary, usual, proper or expedient in this regard."

8. Approval of Material Related Party Transactions with JC Biotech Private Limited, Subsidiary

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 188(1) and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 23 and other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof), Policy on Related Party Transactions of the Company and based upon the recommendation of the Audit Committee and the Board of Directors of the Company, approval of the Members of the Company be and is hereby accorded to enter into contract / arrangement / transactions with 'JC Biotech Private Limited' (a subsidiary of the Company), from the date of ensuing 37th Annual General Meeting (AGM) of the Company till the date of 38th AGM, as per the details provided in the Explanatory Statement attached to this Notice, and on such terms and conditions as may be decided by the Board of Directors of the Company, from time to time.

RESOLVED FURTHER THAT the Board of Directors of the Company and / or any Committee thereof be and is hereby authorized to settle any question, difficulty or doubts that may arise and to do all such acts, deeds and things as may be necessary, usual, proper or expedient in this regard."

By Order of the Board of Directors

Sanjay Basantani

Place: Thane Company Secretary and Head – Legal
Date: July 04, 2026 Membership No.: A19637

Registered Office:

Sun Magnetica, A-Wing,
5th Floor, Louiswadi, LIC Service Road
Thane (W) - 400 604, Maharashtra, India

NOTES:

1. The Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 ("**Act**"), Secretarial Standard-2 on General Meetings and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) in respect of the Special Business and information on Ordinary Business in respect of item no. 3 is annexed hereto.
 2. Pursuant to the General Circular Nos. 14/2020, 17/2020, 20/2020 dated April 08, 2020, April 13, 2020, May 05, 2020 respectively read with the General Circular No. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs (collectively "**MCA Circulars**") and in compliance with the applicable provisions of the Companies Act, 2013 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("**Listing Regulations**"), the 37th Annual General Meeting of the Company ("**37th AGM**" / "**AGM**") is being held through VC/OAVM Facility, which does not require physical presence of Members at the venue. The proceedings of the 37th AGM shall be deemed to be made conducted at the Registered Office of the Company situated at 5th Floor, A Wing, Sun Magnetica, LIC Service Road, Louiswadi, Thane (W), Maharashtra – 400604, India.
 3. Pursuant to the approval / authority of the Board of Directors of your Company ("**Board**"), Friday, July 24, 2026 is fixed as the 'Record Date' for the purpose of determining entitlement of the Members to the final Dividend for the Financial year 2025-26, if declared at the AGM. Subject to the provisions of the Act, the final Dividend as recommended by the Board, if declared at the AGM will be paid on or after August 03, 2026 to those Members whose names appear: (a) in the Register of Members of the Company as on close of the business hours on Friday, July 24, 2026 and (b) as beneficial owners as at the end of business hours of Friday, July 24, 2026 as per the list furnished by National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) in respect of Shares held in Dematerialised form.
 4. Members are requested to note the following:
 - a) Members holding shares in physical form are requested to intimate any change in their address, name, bank details, ECS mandates, nominations, Power of Attorney, etc. to the Company's Registrar to an Issue and Share Transfer Agent, MUFG Intime India Pvt. Ltd. (formerly Link Intime India Private Limited), C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400 083 ("**RTA**" / "**R&T Agent**"). Kindly quote the ledger folio number in all your correspondence. For updation of the bank account details / mandate, kindly send the scan copy of a signed request letter mentioning therein the name, folio number, bank account details, self-attested copy of PAN card / Form ISR-1 and Form ISR-2 (as applicable, refer note no. 9 below) and a cancelled cheque leaf with pre-printed name of the Member (first shareholder) of the Company, to the Registrar to an Issue and Share Transfer Agent.
 - b) Members holding shares in dematerialized form are requested to intimate any change in their address, name, bank details, ECS mandates, nominations, Power of Attorney, etc. to their respective Depository Participants (DPs) only. Kindly quote client ID and DP ID numbers in all your correspondence.
 5. Pursuant to the provisions of the Income Tax Act, 2025 (as amended from time to time) the Company would be under an obligation to deduct tax at source ("**TDS**") in accordance with the provisions of the IT Act, from the final Dividend, if approved by the Members at the AGM. In this regard, the Members may refer the Note on TDS on Dividend distribution, appended to this Notice convening 37th AGM of the Company ("**AGM Notice**").
 6. The 37th Integrated Annual Report along with AGM Notice including general guidelines for participation at the 37th AGM through VC/OAVM, procedure for remote e-voting including during the AGM, is being sent by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depository. The said documents are also being uploaded on the website of the Company. Integrated Annual report of the Company can be accessed and downloaded from www.advancedenzymes.com/investors/annual-report/
- SEBI vide its Master Circular No. HO/38/13/(4)2026-MIRSD-POD/1/4298/2026 dated February 06, 2026 ("**SEBI Circulars**") and the FAQs released by the SEBI has provided common and simplified norms for processing investor's service request by RTAs and norms for furnishing PAN, KYC and Nomination details. Further as per the said SEBI Circular, the Shareholders holding shares in physical form and who have not updated their KYC details (viz., PAN; Choice of Nomination; Contact Details; Mobile Number; Bank Account Details and signature) against their folio on or after April 01, 2024 with MUFG Intime India Private Limited, Registrar to an Issue and Share Transfer Agent of the Company ("**RTA**"), their dividend shall be withheld by the Company and the same shall be immediately released electronically, upon updation of KYC.
- Further pursuant to the amendment in the Listing Regulations with effect from November 19, 2025, Dividend, if declared, will only be paid through electronic modes and 'payable-at-par' warrants or cheques will not be issued for payment of dividend.
- To support the 'Green Initiative' and in accordance with MCA Circulars and SEBI Circulars, copy of the

Integrated Annual Report is being sent only through emails to the Members of the Company. Members who have not registered their e-mail addresses are requested to register the same with the Company or with the Company's R&T Agent / respective Depository Participant(s). Additionally, in accordance with Regulation 36(1)(b) of the SEBI Listing Regulations, a letter is also being sent by the Company to those Members, whose e-mail addresses are not registered, providing the web-link and QR Code including the exact path of the Company's website from where the Notice and Integrated Annual Report for FY 2025-26 is available and can be accessed. In case any Member needs the physical copy of the Integrated Annual report for FY2025-26, the request shall be sent to the registered office of the Company or emailed to the Company at cs@advancedenzymes.com mentioning their Folio No./ DP ID and Client ID.

7. Members are requested to note that as per Section 124 of the Companies Act, 2013, Dividends not claimed within seven years from the date of transfer to the Company's Unpaid Dividend Account shall be transferred to the Investor Education and Protection Fund of the Government ("IEPF"). Unclaimed Dividends as per details given in the table below are due to be transferred to the 'Investor Education and Protection Fund' on the dates mentioned below:

Financial Year	Type of Dividend	Date of Declaration	Due date for transfer to IEPF	Indicative date of transfer to IEPF
2018-19	Final Dividend	August 08, 2019	September 13, 2026	October 12, 2026
2019-20	Final Dividend	July 15, 2020	August 20, 2027	September 18, 2027
2020-21	Final Dividend	September 08, 2021	October 09, 2028	November 07, 2028
2021-22	Final Dividend	August 19, 2022	September 22, 2029	October 21, 2029
2023-24	Interim Dividend	May 13, 2023	June 15, 2030	July 14, 2030
2022-23	Final Dividend	August 12, 2023	September 13, 2030	October 12, 2030
2024-25	Interim Dividend	May 11, 2024	June 13, 2031	July 12, 2031
2023-24	Final Dividend	July 25, 2024	August 26, 2031	September 24, 2031
2025-26	Interim Dividend	May 13, 2025	June 16, 2032	July 15, 2032
2024-25	Final Dividend	July 30, 2025	September 01, 2032	September 30, 2032

Note: Those Members who have not, so far, encashed these Dividend warrants or any subsequent Dividend warrants may claim or approach our Registrar to an Issue and Share Transfer Agent viz. MUFG Intime India Private Limited or the Company for payment thereof. Members are hereby informed that the Unclaimed Dividend amount shall be transferred by the Company to the IEPF within the period of thirty (30) days from the aforementioned due date(s) or such other period

as may be specified under the Companies Act, 2013 and rules made thereunder, from time to time and no claims will be entertained by the Company for any unclaimed Dividend transferred to the IEPF. The details of unclaimed Dividends and its due dates for transfer to the IEPF are available on the website of the Company: www.advancedenzymes.com/investors/shareholder-information

Section 124(6) of Companies Act, 2013 and rules made thereto, provides that all shares in respect of which Dividend has not been paid or claimed for seven consecutive years or more shall also be transferred to the IEPF Authority. The Company will be sending the intimation letter to the concerned Members as per the last registered address available with the Company, regarding their respective unclaimed Equity Shares / unclaimed Dividend due for transfer on or after September 13, 2026, as mentioned above. Details are available on the website of the Company, at www.advancedenzymes.com. The concerned Members are requested to submit the claim along with requisite documents before September 13, 2026 to avoid transfer of shares/Dividend to the IEPF Account. No claim shall lie against the Company after the shares are transferred to the IEPF. Upon transfer, the Members can claim these Equity Shares from the IEPF Authority by following the requisite procedure, the details of which are also available at www.iepf.gov.in. Hence, it is in the interest of the Members to claim any uncashed Dividends and for future, opt for Electronic Credit of Dividend, so that Dividends paid by the Company are credited to the Member's bank account on time.

8. Corporate Members intending to attend the AGM through VC/OAVM are requested to send a scanned copy of the certified true copy of Board Resolution / Power of Attorney from the Corporate Member's registered email address authorizing their representative(s) to attend the AGM on their behalf, at the email ID, cs@advancedenzymes.com. Further, the Corporate Members are requested to also state the Client ID/DP ID in which the shares of the Company are held.
9. Members holding shares in physical form can avail the nomination facility by submitting Form SH-13, as prescribed under Section 72 of the Companies Act, 2013 and rules made thereunder, with the Company. Members holding shares in demat form may contact their respective Depository Participant(s) for availing the nomination facility. The Securities and Exchange Board of India ("SEBI") vide its circular as mentioned in Point No.: 4 above and the FAQs released by the SEBI have provided common and simplified norms for processing investor's service request by RTAs and norms for furnishing PAN, KYC and Nomination details.

SEBI has issued FAQ's in this regard, which are available on the website of SEBI at https://www.sebi.gov.in/sebi_data/faqfiles/jan-2026/1767611333081.pdf.

The brief process to update PAN, KYC details and Nomination along with relevant forms are also available on the website of the Company, under the head 'Investors Service Request' at www.advancedenzymes.com/investors/shareholder-information/ and website of the RTA at <https://web.in.mpms.mufig.com/KYC-downloads.html>.

The concerned Members who have not yet updated the said details (PAN/KYC/Nomination) are requested to peruse and submit the requisite form/documents as mentioned above.

10. a) As per Regulation 40 of the SEBI Listing Regulations (as amended), requests for effecting transfer of Securities, shall not be processed unless the Securities are held in the dematerialized form and the transmission or transposition of Securities held in physical or dematerialised form shall be effected only in dematerialised form. Hence, the Members holding Equity shares of the Company in physical form are requested to take action to dematerialize the same promptly. The Members may also note that as per the SEBI Circular SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, the Company is required to issue the Securities in dematerialized form only, while processing the service requests in relation to issue of duplicate securities certificate, claim from Unclaimed Suspense Account, renewal / exchange of securities certificate, endorsement, sub-division / splitting of securities certificate, consolidation of securities certificates/folios/ transmission and transposition of securities.
- b) SEBI vide its Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 06, 2026 has simplified the procedure and standardized the format of documents for transmission of securities and issuance of duplicate securities certificates respectively. The relevant Forms, in this regard, have been made available on the website of the Company at www.advancedenzymes.com/investors/shareholder-information/.
11. The brief profile and other requisite details of the Directors recommended by the Board for appointment/reappointment at the 37th AGM under Item No. 3, 5 and 6 of this Notice, as required by the SEBI Listing Regulations and Secretarial Standard on General Meetings (SS-2), are furnished on Page No. 21-22 of the AGM Notice.
12. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act, and the Register of Contracts or Arrangements in which the Directors are interested under Section 189 of the Act will be available for inspection during the AGM electronically. Further a certificate from the Secretarial Auditor of the Company, pertaining to the AETL ESOP Scheme 2022, as prescribed under Regulation 13 of the Securities and Exchange Board of India (Share Based

Employee Benefits and Sweat Equity) Regulations, 2021 will also be available for inspection up to the date of the 37th Annual General Meeting.

13. All the relevant documents referred in the Notice shall be available for inspection by the Members upto the date of 37th Annual General Meeting at the Registered Office of the Company on all working days, except Saturdays and Sundays, between 11:00 a.m. to 1:00 p.m.
14. SEBI circular no. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/131 dated July 31, 2023 (updated vide Master Circular SEBI/HO/OIAE/OIAE_IAD-3/P/CIR/2023/195 as on December 20, 2023), *inter alia* states that to resolve a grievance, the Member shall first take up the grievance with the listed entity. If the grievance is not resolved satisfactorily, the Member can escalate it through the SCORES Portal following the specified guidelines. If the Member is not satisfied with the outcome, the Member can initiate the dispute resolution through the Online Dispute Resolution ("ODR") Portal (<https://smartodr.in/login>) and the same can also be accessed through the website of the Company at <https://www.advancedenzymes.com>. Members may peruse the said Master Circular for details.
15. **General Instructions for accessing and participating at the 37th AGM through Electronic Means (VC/OAVM)**
 - i) Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of the SEBI Listing Regulations (as amended), and the MCA Circulars issued by the Ministry of Corporate Affairs, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited ("NSDL") for facilitating voting through electronic means, as the authorized e-Voting agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by NSDL.
 - ii) The Members may join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the AGM by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 Members on first come first served basis. This will not include large Shareholders (Members holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairperson of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

- iii) The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.
 - iv) Pursuant to the proviso to Regulation 44(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024, the requirement of sending proxy forms is dispensed with in case of general meetings held through electronic mode only. Pursuant to the MCA Circulars, the facility to appoint proxy to attend and cast vote for the Members is not available for this AGM being conducted through VC/OAVM. However, in pursuance of Section 112 and Section 113 of the Act, representatives of the Members such as the President of India or the Governor of a State or Body Corporates can attend the AGM through VC/OAVM and cast their votes through e-voting, subject to the applicable conditions as mentioned in Note No. 21 below.
 - v) Notice of the 37th AGM has been uploaded under the tab 'Shareholders Meetings' on the website of the Company at www.advancedenzymes.com/investors/announcements-notices/. The Notice can also be accessed from the website of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively. The AGM Notice is also disseminated on the website of NSDL i.e. www.evoting.nsdl.com
 - vi) AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with the MCA Circulars.
 - vii) The recorded transcript of the 37th AGM shall be made available on the website of the Company, www.advancedenzymes.com under the tab "Shareholders Meetings" in the Investors section, after the conclusion of the AGM as soon as possible.
- 16. Process for those Members whose email addresses are not registered with the Depositories for obtaining login credentials for e-voting on the Resolutions set out in this Notice:**
- i) In case shares are held in physical mode, please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of masked AADHAR Card) by email to cs@advancedenzymes.com.
 - ii) In case shares are held in Demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), masked AADHAR (self-attested scanned copy of AADHAR Card) to cs@advancedenzymes.com. If you are an Individual shareholder holding securities in Demat mode, you are requested to refer to the login method explained in Note no.18 (iii) (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in Demat mode.
 - iii) Alternatively, shareholders/Members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.
 - iv) In terms of the SEBI circular dated December 09, 2020 on e-Voting facility provided by listed companies, Individual shareholders/Members holding securities in Demat mode are allowed to vote through their Demat account maintained with Depositories and Depository Participants. Members are required to update their mobile number and email ID correctly in their Demat account in order to access e-Voting facility.
- 17. Voting through electronic means:**
- The Company is pleased to provide remote e-voting facility through National Securities Depository Limited (NSDL) for the Members of the Company to enable them to cast their votes electronically on the resolutions mentioned in this Notice of 37th Annual General Meeting of the Company dated May 09, 2026 ("Notice"). The details and instructions for remote e-voting are furnished in Note Nos. 18, 20 and 21 of the AGM Notice. These details form an integral part of the Notice.
- 18. Procedure for Remote E-Voting: The instructions for the Members voting electronically are as under:**
- i) The remote e-voting period begins on Monday, July 27, 2026 at 09:00 a.m. (IST) and ends on Thursday, July 30, 2026 at 05:00 p.m. (IST). During this period, the Members, whose names appear in the Register of Members / Beneficial Owners as on the cut-off date i.e. Friday, July 24, 2026 may cast their vote electronically. The e-voting module shall be disabled by NSDL for voting thereafter.
 - ii) The Members who have already voted prior to the meeting date would not be entitled to vote during the meeting.
 - iii) Pursuant to the Regulation 44 of the SEBI Listing Regulations, the listed entities are required to provide remote e-voting facility to its Members, in respect of all shareholders' resolutions. Further, as per the SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 09, 2020, it is mentioned in the circular that currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the Members. In order to increase the efficiency

of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in Demat mode

In terms of SEBI circular dated December 09, 2020 on e-Voting facility provided by listed companies, Individual shareholders/Members holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Members are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders/Members holding securities in demat mode is given below:

Type of Members	Login Method
Individual Members holding securities in Demat mode with NSDL	1) For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2) Existing IDeAS user can visit the e-Services website of NSDL viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 3) If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 5) Shareholders/Members can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR code mentioned below for seamless voting experience. NSDL Mobile App is available on  App Store  Google Play  

Type of Members	Login Method
Individual Members holding securities in Demat mode with CDSL	1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2) After successful login, the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by the company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from an e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their Depository Participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. Upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on Company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Members holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL

Login type	Helpdesk details
Individual Members holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at +91- 22 - 4886 7000
Individual Members holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meeting for shareholders/Members other than Individual shareholders/Members holding securities in Demat mode and shareholders/ Members holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

- 1) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.

- 2) Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
- 3) A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step (2) i.e. cast your vote electronically.
- 4) Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5) Password details for the Members/ shareholders other than Individual shareholders/Members are given below:

- a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- c) How to retrieve your 'initial password'?
 - i) If your email ID is registered in your Demat account or with the Company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - ii) If your email ID is not registered, please follow steps mentioned below in process for those Members whose email ids are not registered.
- 6) If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

- a) Click on "Forgot User Details/ Password?" (If you are holding shares in your Demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
- b) "Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
- c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your Demat account number/folio number, your PAN, your name and your registered address etc.
- d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

- 7) After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
- 8) Now, you will have to click on "Login" button.
- 9) After you click on the "Login" button, Home page of e-Voting will open.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

- 1) After successful login, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
- 2) Select "EVEN" of the Company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".
- 3) Now you are ready for e-Voting as the Voting page opens.
- 4) Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
- 5) Upon confirmation, the message "Vote cast successfully" will be displayed.
- 6) You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
- 7) Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for Members

- i) Institutional shareholders/Members (i.e. other than individuals, HUF, NRI etc.) are required to upload their Board Resolution / Power of Attorney / Authority Letter by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab on this screen or send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail (office@csshjco.com) with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
- ii) It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
- iii) In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: +91-22-4886 7000 or send a request to Mr. Sanjeev Yadav at evoting@nsdl.com.

In addition, any query / grievance with respect to the voting by electronic means may be addressed to the Company at cs@advancedenzymes.com / investor.grievances@advancedenzymes.com

Other Instructions/information:

- i) The voting rights of the Members shall be in proportion of the shares held by them in paid-up Equity share capital of the Company as on the Cut-Off Date i.e. Friday, July 24, 2026. A person who is not the Member as on Cut-Off Date should treat this Notice for information purpose only.
- ii) Any person holding shares in physical form and non-individual Members, who acquires shares of the Company and becomes Member of the Company after the Notice is sent through e-mail, and holding shares as of the cut-off date i.e. Friday, July 24, 2026 may obtain the login ID and password by sending a request at evoting@nsdl.com or Issuer/RTA. However, if you are already registered with NSDL for remote e-voting, then you can use your existing user ID and password for casting your vote. If you forgot your password, you can reset your password

by using "Forgot User Details/Password" or "Physical User Reset Password" option available on www.evoting.nsdl.com or call on +91-22-4886 7000. In case of Individual Members holding securities in Demat mode who acquire shares of the Company and become a Member of the Company after sending Notice of AGM, and holding shares on the cut-off date i.e. Friday, July 24, 2026 may follow steps mentioned in the Notice of the AGM under "Access to NSDL e-Voting system."

- iii) Mr. Shiv Hari Jalan, Proprietor of Shiv Hari Jalan & Co., Company Secretary in practice (C.P. No. 4226) has been appointed as the Scrutinizer to scrutinize the e-voting process (including the remote e-voting at the Annual General Meeting) in a fair and transparent manner.
- iv) The Scrutinizer shall, within the timelines prescribed under the applicable law, after the conclusion of the e-voting period and conclusion of AGM, unblock the votes in the presence of at least two witnesses (not in the employment of the Company) and the consolidated Scrutinizer's Report of the votes cast in the favor or against, if any, shall be submitted to the Chairman of the AGM or any person authorized by him. Within two working days from the conclusion of the AGM, the voting results shall be intimated by the Company to NSDL and the Stock Exchanges where the Company's securities are listed, and shall be displayed along with the Scrutinizer's report on the Company's website (www.advancedenzymes.com) and NSDL's website (www.evoting.nsdl.com). Subject to receipt of requisite number of votes, the Resolutions shall be deemed to be passed on the date of 37th AGM i.e. July 31, 2026.
- v) Members who are present at AGM through VC/OAVM and have not used the facility of remote e-voting during the above mentioned e-voting period to cast their votes on the resolution(s) mentioned in the Notice, and are otherwise not barred from doing so, shall be provided e-voting facility at the AGM.
- vi) Members can opt for only one mode of voting i.e. either through remote e-voting during e-voting period before the AGM date or remote e-voting during the AGM subject to the Member(s) joining the AGM through VC/OAVM.
- vii) The details of dispatch of Notice to the Members will be published in at least 1 (one) English and 1 (one) vernacular language newspaper circulating in Maharashtra.

19. Instructions for Members attending the AGM through VC/OAVM are as under:

- i) Members will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by

following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM link" placed under "**Join meeting**" menu against Company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of the Company will be displayed. Please note that the Members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the Notice to avoid last minute rush.

- ii) Members are encouraged to join the Meeting through Laptops for better experience.
- iii) Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
- iv) Please note that participants connecting from Mobile devices or Tablets or through Laptop connecting via Mobile hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
- v) Members who would like to express their views/ask questions during the AGM may register themselves as a speaker by sending their request from their respective registered email id(s) in advance atleast 48 hours before the commencement time of 37th AGM, mentioning their name, demat account number/folio number, email id, mobile number at cs@advancedenzymes.com. Members who do not wish to speak during the AGM but would like to seek further information or clarification on the Annual financial statements or operations of the Company, may send their queries from their registered email id(s) in advance atleast 7 (seven) days prior to the AGM date, mentioning their name, demat account number/folio number, email id, mobile number at cs@advancedenzymes.com, so that the queries can be suitably replied by the Company.
- vi) Those Members who have registered themselves as a speaker, as mentioned above, will only be allowed to express their views/ask questions as speaker during the AGM.

20. Instructions for Members for e-voting during the AGM are as under:

- i) The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting.
- ii) Only those Members as on Friday, July 24, 2026 (cut-off date) and who are present for the AGM through VC/OAVM facility and have not cast their vote on the Resolutions through remote e-voting earlier and are otherwise not barred from doing so, shall be eligible to vote through e-voting system available during the AGM (www.evoting.nsdl.com).
- iii) If any votes are cast by the Members through the e-voting available during the AGM and if the same Members have not participated in the meeting through VC/OAVM facility, then the votes cast by such Members shall be considered invalid as the facility of e-voting during the AGM is available only to the Members attending the AGM through VC/OAVM.
- iv) The Members who have voted through Remote e-voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
- v) The details of the person who may be contacted for any queries/grievances connected with the facility for e-Voting on the day of the AGM or attending AGM through VC/OAVM facility shall be the same person mentioned for Remote e-voting above.

21. Note for Non - Individual Members and Custodians.

Non Individual Members are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz. cs@advancedenzymes.com or office@csshjco.com, if they have voted from individual tab and not uploaded same in the NSDL e-voting system for the scrutinizer to verify the same.

- 22. As the 37th AGM shall be held through VC/OAVM facility only and physical presence of the Members at the venue is not required, the route map is not annexed to the Notice.

INFORMATION PERTAINING TO THE ORDINARY BUSINESS ITEM REGARDING THE RE-APPOINTMENT OF THE STATUTORY AUDITORS

Item No. 4

The Members of the Company, at the 32nd Annual General Meeting (“AGM”) held on September 08, 2021, approved the appointment of MSKA & Associates, Chartered Accountants (Firm Registration No. 105047W) (“MSKA”), as the Statutory Auditors of the Company for a period of 5 (Five) consecutive years from the conclusion of the 32nd AGM until the conclusion of 37th AGM of the Company, pursuant to the provisions of Section 139 of the Companies Act, 2013 (“Act”) read with the Companies (Audit and Auditors) Rules, 2014 (as amended). Accordingly, MSKA will complete its current term as the Statutory Auditors, on conclusion of this 37th AGM. Pursuant to the provisions of the sub-section (2) of Section 139 of the Act, an audit firm can be appointed for two terms of five consecutive years.

The last remuneration of MSKA in connection with the Statutory Audit/limited review for the financial year 2025-26 as mutually agreed and approved by the Board was ₹ 4.2 million (excluding taxes) and out-of-pocket expenses and administrative expenses not exceeding 4% of ₹ 4.2 million.

MSKA has informed the Company that the firm has been converted into a Limited Liability Partnership (LLP) with effect from January 13, 2026 and that the name has changed from MSKA & Associates to MSKA & Associates LLP (Firm Registration No. 105047W/ W101187).

Basis of recommendation for re-appointment and credentials of the Statutory Auditors:

Established in 1978, MSKA & Associates LLP, a member firm of BDO International, is an Indian Limited Liability Partnership firm registered with the Institute of Chartered Accountants of India (ICAI) and the PCAOB (US Public Company Accountancy Oversight Board). MSKA has more than 100 Partners/Directors and over 2500 staff and provides range of services *inter alia* under Audit & Assurance including Tax audit and Internal Financial Controls Audit. The firm has presence in 14 key cities in India.

The Board/Audit Committee considered various parameters such as audit experience, market standing of the firm, clientele served, technical knowledge etc., and found that qualifications and experience are commensurate with the size and requirements of the Company.

MSKA has provided the confirmation and consent to the Company that they are eligible for reappointment as the Statutory Auditors and reappointment, if made, will be in accordance with the conditions prescribed under Section 139 and 141 of the Companies Act, 2013. They have further confirmed that they have subjected themselves to the peer review process of the Institute of Chartered Accountants of India (ICAI) and holds a valid certificate issued by the ‘Peer Review Board of ICAI’.

Proposed fees and the terms of appointment:

The Board of Directors of the Company (“Board”) at its meeting held on May 09, 2026, based on the recommendations of the Audit Committee, approved and recommended to the Members, the reappointment of M/s. MSKA & Associates LLP, Chartered Accountants (Firm Registration No. 105047W/ W101187) (“MSKA”), as the Statutory Auditors of the Company, for a second term of 5 (Five) consecutive years from the conclusion of this 37th AGM till the conclusion of the 42nd AGM of the Company at an annual remuneration not exceeding ₹ 4.4 million excluding taxes, out-of-pocket expenses and administrative expenses not exceeding 4% of ₹ 4.4 million, for the financial year 2026-27 in connection with the statutory audit/limited review, as applicable. Other certification charges and scope of work as may be approved by the Board and/or mutually agreed. As per the approval sought from the Members in Resolution No. 4, the remuneration for the balance period shall be decided by the Board based on the recommendations of the Audit Committee.

None of the Directors or Key Managerial Personnel of the Company or their Relatives are concerned or interested financially or otherwise in the resolution.

The Board recommends the resolution set out at Item No. 4 to be passed as an **Ordinary Resolution**.

**EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013, SECRETARIAL
STANDARD-2 (SS-2) ON GENERAL MEETINGS AND THE SECURITIES AND EXCHANGE BOARD OF INDIA
(LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)**

Item No. 5

The Members of the Company at their meeting held on September 08, 2021 re-appointed Mr. Mukund Kabra as Whole-Time Director of the Company for a period of 5 (five) years effective from April 01, 2022 to March 31, 2027. Accordingly, his tenure as Whole-Time Director ends on March 31, 2027. In view of this and based on the recommendations of Nomination and Remuneration Committee, the Board of Directors of the Company ("Board"), at its meeting held on May 09, 2026, has approved and recommended the re-appointment of Mr. Mukund Madhusudan Kabra (DIN: 00148294) as Whole-Time Director of the Company for another term of 5 years effective from April 01, 2027 to March 31, 2032, for the approval of the Members.

Brief profile and expertise in specific functional area:

Mr. Mukund Kabra, Whole-time Director of the Company, has around 31 years of experience in the enzyme industry and has been associated with the Company since 1995. He holds a Bachelors' degree in Chemical Engineering from Sambalpur University. Mr. Kabra is responsible for overlooking the manufacturing operations of the Company and for optimising the fermentation for existing products, strain improvement, downstream and analytical research. He has also been nominated on the Board of various subsidiaries of the Company.

The material terms of re-appointment are as follows:

Remuneration:

- a) Basic Salary: In the range of ₹ 0.65 million per month to ₹ 2.50 million per month. Increase in Basic Salary to align and comply with the applicable laws in India, as may be amended or enacted from time to time, solely to the extent of such restructuring will not be considered as an increase in his Basic Salary, and the range / ceiling mentioned herein will be deemed to be increased to that extent accordingly, provided that the total Annual Remuneration to Mr. Kabra in a financial year shall not exceed the amount, subject to annual increment(s), as mentioned in clause (e) below.
- b) Allowances: Such as House Rent Allowance, Compensatory Allowance, Education Allowance, Special Allowance, any other allowance as per the rules of the Company and payable every month or annually.
- c) Commission: As may be determined and recommended by Nomination and Remuneration Committee with reference to the net profits for each financial year, and as may be approved by the Board of Directors of the Company, subject to the provisions and limits specified under Companies Act, 2013 and rules made thereunder (as amended from time to time).
- d) Perquisites:

Category – A

He will be entitled to various perquisites including Medical Reimbursement, Leave Travel Concession,

Club Fees (subject to maximum of two clubs excluding admission and life membership fees), Personal Accident Insurance, Medical Insurance, Incentive, Ex-gratia etc., in accordance with the rules of the Company. The aforesaid perquisites may be in the form of allowances or reimbursement. The aforesaid perquisites will be restricted to aggregate of Salary.

Category – B

The Company's contribution to Provident Fund, Superannuation Fund and Annuity Fund, benefits of the Pension and Gratuity Scheme, Leave entitlement, Earned Leave and Encashment of earned leave and long service awards, will be in accordance with the Rules and Regulations of the Company and will be allowed in addition to Salary.

Category – C

Car for the use on Company's business, telephone and communication facilities at residence.

- e) Annual Remuneration & annual increments: Annual increment not exceeding 30% of the relevant previous year' Annual Remuneration with first such annual increment due from April 01, 2027, as may be recommended by the Nomination & Remuneration Committee and approved by the Board of Directors of the Company. The said Annual Remuneration of Mr. Kabra was ₹ 28.65 million for financial year ended March 31, 2026. For the purpose of clause (a) above and this clause (e), the term '**Annual Remuneration**' excludes Commission, leave encashment, if any, and ESOP/stock options and other exclusions, if any permissible under the Act, from time to time.

Other terms:

- i) Reimbursement of Expenses: Reimbursement of travelling, entertainment and other expenses including amount spent on newspaper and business magazines incurred by him during the course of the business of the Company.
- ii) Sitting fees: He is not entitled to sitting fees for attending meetings of the Board or of a committee thereof.
- iii) Stock Options: Mr. Kabra shall be eligible for stock options as granted/may be granted by time to time by the Nomination & Remuneration Committee under the applicable provisions of the Employee Stock Option Scheme of the Company, subject to the provisions of the applicable laws.
- iv) Termination Clause: The appointment shall be terminable by either party i.e. by the Company or by Whole-time Director by giving three months' notice.

Minimum Remuneration:

Notwithstanding anything mentioned herein where, in any financial year, during the currency of tenure of Mr. Mukund Kabra, the Company has no profits or its profits are inadequate, the Company will pay the remuneration by way of salary and perquisites as specified above, subject to such approvals, as may be required and the applicable provisions of the Act.

Pursuant to the provisions of the Act, Mr. Mukund Kabra shall also be liable to retire by rotation and shall also continue to be the Key Managerial Personnel of the Company.

Subject to approval of the Members of the Company, the Agreement incorporating mainly the aforesaid terms and conditions shall be entered into between the Company and Mr. Mukund Kabra as Whole-time Director. The draft of the Agreement shall be available for inspection electronically by the Members up to the date of 37th Annual General Meeting and the eligible Member(s) may send a request for inspection of the draft Agreement to the Company Secretary at cs@advancedenzymes.com and mention the details of Folio No. or Client ID/DP ID wherein the shares of the Company are held by the Member(s).

The Explanatory statement together with the accompanying Notice shall be treated as an abstract of the terms of the Agreement and Memorandum under Section 190 of the Act.

The Company has received consent from Mr. Mukund Kabra to act as Whole Time Director of the Company along with a declaration/confirmation to the effect that: (i) he is not disqualified from being appointed as a Director in terms of Section 164 of the Companies Act, 2013 and has not been debarred or disqualified from being appointed or continuing as Director of a Company by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority; and (ii) he satisfies all the conditions set out in Part-I of Schedule V to the Act as also conditions set out under sub-section (3) of Section 196 of the Act for being eligible for re-appointment. Further, the Company has also received notice under Section 160 of the Act from a member proposing the candidature of Mr. Mukund Kabra as Director of the Company.

Members may kindly note that the Company has adequate profits under Section 198 of the Act and the proposed remuneration of Mr. Kabra is within the overall limits prescribed under Section 197 of the Act read with Schedule V and rules made thereunder.

Brief profile and the information as required under the provisions of SEBI Listing Regulations and Secretarial Standards-2 on General Meetings is provided on page no. 21-22 of this Notice.

Except Mr. Mukund Kabra to the extent mentioned above and his Relatives who may be deemed to be interested, none of the Directors or Key Managerial Personnel of the

Company or their relatives are in any way, concerned or interested, financially or otherwise.

The Board recommends the resolution set out in Item No. 5 to be passed as an **Ordinary Resolution**.

Item No. 6

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company in its meeting held on May 09, 2026 appointed Mr. Pradip Bhailal Shah (DIN: 01225582) as an Additional Director (Independent), with effect from June 12, 2026, and to hold office of an Independent Director for a term of 5 (Five) years subject to approval of the Members of the Company.

The Company has received a notice in writing from a Member under Section 160 of the Companies Act, 2013 ("Act") proposing the candidature of Mr. Shah as an Independent Director of the Company.

Mr. Shah has provided the consent to act as a Director of the Company and a declaration/confirmation: (i) under sub-section (7) of Section 149 of the Companies Act, 2013 (as amended) ["Act"] stating that he meets the criteria of independence as provided in sub section (6) of Section 149 of the Act and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ["SEBI Listing Regulations"]; (ii) that he has complied with the Rules 6(1) and 6(2) of the Companies (Appointment and Qualifications of Directors) Rules, 2014 (as amended) and he is not disqualified from being appointed as a Director in terms of Section 164 of the Act; (iii) that he is not debarred from holding office of Director pursuant to any order of SEBI, Ministry of Corporate Affairs or any such other Statutory Authority; and (iv) that he is not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact his ability to discharge his duties with an objective independent judgment and without any external influence.

Brief profile: Mr. Pradip Shah is a veteran entrepreneur, operator, and investor with four decades of experience in building and leading businesses in the United States. He is a Co-Founder and Chief Executive Officer ("CEO") of Washington Garment Dyeing & Finishing, Inc., US ("WGDF"). He served as Vice – President of WGDF for over two decades and assumed the role of CEO in 2012 of WGDF. He has around four decades experience of running the industrial business. He also served as a Director on the Board of the Company from 1993 till 2016. His areas of expertise among others include financial operations and control, cross border investment, working capital and cash flow management, founder CEO leadership and real estate ownership and management.

In the opinion of the Board, Mr. Shah fulfils the conditions and requirements specified in the Act and rules made thereunder, SEBI Listing Regulations, Policy on Board Diversity read with the Nomination and Remuneration Policy and is independent of the management of the Company and that having regards to his qualifications, knowledge, expertise and experience, he possesses the skills/competencies/expertise in the field of financial operations & control including working capital & cash flow management, leadership and understanding of global business and his appointment as an Independent Director will be in the best interest of the Company. Accordingly, the Board recommends the Special Resolution set out at item no. 6 of this Notice for approval of the Members.

Mr. Shah will be paid sitting fees for attending meetings of the Board and Committees thereto of which he is a Member/Chairperson and commission which may be recommended by the Nomination and Remuneration Committee and approved by the Board of Directors of the Company, as authorized by the Members in the 34th Annual General Meeting of the Company held on August 12, 2023.

Eligibility declaration and other relevant disclosures under the Act and the SEBI Listing Regulations received from him and draft of the appointment letter, are open for inspection at the Registered Office of the Company on all working days, except Saturdays and Sundays, between 11:00 a.m. and 1:00 p.m. up to the date of 37th Annual General Meeting.

Other requisite details including brief profile of Mr. Shah as required under the SEBI Listing Regulations and the Secretarial Standards on General Meetings (SS-2) is provided on page no. 21-22 of this Notice.

In accordance with the provisions of Section 149 read with Schedule IV to the Act and Regulation 25 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), appointment of Independent Director requires approval of Members by way of a Special Resolution. Additionally, as per Regulation 17(1A) of the SEBI Listing Regulations, the continuation of a Non-Executive Director beyond the age of 75 years requires the approval of shareholders by way of a Special Resolution. Mr. Shah will attain the age of 75 years during his current tenure. In view of the above and the justification as mentioned above, the approval of the Members of the Company is being sought by way of a Special Resolution.

Except Mr. Pradip Shah to the extent mentioned above and his Relatives who may be deemed to be interested, none of the Directors or Key Managerial Personnel of the Company or their relatives are in any way, concerned or interested, financially or otherwise.

The Board of Directors of the Company recommends the resolution set out in Item No. 6 to be passed as a **Special Resolution**.

Item No. 7

Pursuant to the provisions of Section 188 (1)(f) of the Companies Act, 2013 read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules 2014 as amended, ("Act") prior approval of the shareholders of the company is required for appointment of any related party to any office or place of profit in the company, its subsidiary company or associate company if such appointment to any office or place of profit is at a monthly remuneration exceeding ₹ 2,50,000.

The term "office or place of profit" inter alia means any office or place where it is held by an individual other than a Director or by any firm, private company or other body corporate and if the individual, firm, private company or body corporate holding it receives anything by way of remuneration, salary, fee, commission, perquisites, any rent-free accommodation, or otherwise.

Ms. Manasi Kabra is the daughter of Mr. Mukund Kabra, who is the Whole Time Director of the Company. Her qualification includes Master of Professional Studies in Applied Economics and Management from Cornell University, SC Johnson College of Business and Bachelor of Science in Business Administration - Business Economics & Management Information System from University of Arizona.

The Board of Directors of the Company, at its meeting held on January 31, 2026, had approved the appointment of Ms. Manasi Kabra as Corporate Strategy Analyst at Cal – India Foods International d/b/a Specialty Enzymes and Probiotics, step-down wholly owned subsidiary of the Company in USA, with effect from February 02, 2026 at a remuneration of USD 25 per hour for minimum 20 hours a week for a total remuneration not exceeding ₹ 2,50,000 per month or equivalent USD. As the remuneration approved was less than the prescribed threshold, the approval of the Members was not required to be obtained.

Further, based on the recommendation of the Audit Committee, the Board at its meeting held on May 09, 2026, revised the rate of remuneration from USD 25 per hour to USD 37 per hour for minimum 20 hours a week effective from October 01, 2026 i.e. total remuneration of up to USD 3,210 per month, subject to the approval of the Members of the Company, as the monthly remuneration will exceed the aforementioned threshold limit. Further, annual increment, if any, on the total remuneration not exceeding 15% of the previous year's annual remuneration as may be decided by the Board or any Committee thereof, from time to time.

The proposed remuneration exceeds the threshold prescribed for Members' approval under the Act, and hence this resolution is proposed and recommended by the Board for the approval of the Members of the Company.

Following are the details of the proposed transaction required as per the applicable provisions of the Act:

Name of the Related Party	Ms. Manasi Kabra
Name of the Director or key managerial personnel who is related, if any;	Mr. Mukund Kabra, Whole-time Director and Key Managerial Personnel
Nature of relationship	Ms. Manasi Kabra is the daughter of Mr. Mukund Kabra
Nature, material terms, monetary value and particulars of the contract or arrangements	Ms. Manasi Kabra works as a Corporate Strategy Analyst at Cal – India Foods International d/b/a Specialty Enzymes and Probiotics, step-down wholly owned subsidiary of the Company. The other terms of her appointment are as mentioned above in the explanatory statement
Any other information relevant or important for the members to take a decision on the proposed resolution	The proposed continuation of the appointment and payment of remuneration to Ms. Manasi Kabra, to an office or place of profit under Section 188 of the Act, is commensurate with her experience, qualifications, job location, and the nature of responsibilities that are associated with the role of a Corporate Strategy Analyst

None of the Directors or Key Managerial Personnel of the Company or their Relatives are concerned or interested financially or otherwise in the resolution, except as mentioned above.

The Board recommends the resolution set out at Item No. 7 to be passed as an **Ordinary Resolution**.

Item No. 8

Advanced Enzyme Technologies Limited ("**Company**") markets its enzyme based products for Pharma Sector through one of its subsidiaries, JC Biotech Private Limited (CIN: U65993TG1991PTC013624), having its registered office at Plot No. 3, Sagar Society, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034, India (hereinafter referred to as "**JCB**"). The Company holds 95.72% shareholding in JCB.

Pursuant to the provisions of Section 188 of the Companies Act, 2013, read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 (including any statutory modification(s) or re-enactments thereof for the time being in force) ("**Act**"), approval of the Members of the Company is required for the Related Party Transactions on account of the sales, purchase or supply of any goods or materials amounting to 10% or more of the turnover of the Company, only if the transaction is either not in ordinary course or not at an arm's length basis.

As per Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 (as amended) ("**SEBI Listing Regulations**"), approval of the Members of the Company is required in case of material Related Party Transactions. Pursuant to the amendment to the SEBI Listing Regulations effective from December 19, 2025, a transaction with a Related Party shall be regarded as material if the transactions, either individually or taken together with previous transactions during a financial year, exceeds the thresholds prescribed under Schedule XII of the said Regulations. In terms of Schedule XII, where the consolidated turnover of a listed entity is up to ₹20,000 crore, a transaction shall be considered material if its value exceeds 10% of the annual consolidated turnover of the listed entity, as per its latest audited financial statements

The proposed transaction limit of the Company with JCB shall exceed the limits prescribed hereinabove for the material Related Party Transactions. The proposed transaction of the Company with JCB will be in the ordinary course of business of the Company and should be on an arm's length basis. However, there may be some transactions that may be done in the interest of the Company basis the justification provided below. Hence as it's a material Related Party transaction under the Act and SEBI Listing Regulations, approval of the Members of the Company for the proposed transactions, with JCB is being obtained.

Minimum information to be provided to the Audit Committee and Shareholders for approval of Related Party Transactions as per Industry Standards:

Part A : Minimum Information of the proposed RPT

S. No.	Particulars of Information	Information provided by the management
A(1) Basic details of the Related Party		
1	Name of the related party	J C Biotech Private Limited (" JCB ")
2	Country of incorporation of the related party	India
3	Nature of business of the related party	Manufacturing and sale of Bio Pharmaceuticals through the process of aerobic fermentation.

A2 - Relationship and ownership of the related party

S. No.	Particulars of Information	Information provided by the management
1	Relationship between the listed entity/ subsidiary (in case of transaction involving the subsidiary) and the related party – including nature of its concern (financial or otherwise) and the following:	JCB is a subsidiary of the Company
2	Shareholding of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party.	Company holds 95.72% shares of JCB.
3	Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity/ subsidiary (in case of transaction involving the subsidiary).	Not Applicable
4	Shareholding of the related party, whether direct or indirect, in the listed entity/ subsidiary (in case of transaction involving the subsidiary)	Not Applicable as JCB does not hold any shares in the Company directly or indirectly.

A3 - Details of previous transactions with the related party

S. No.	Particulars of Information	Information provided by the management									
1	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the last financial year.	<table> <tr> <th>Sr. No.</th><th>Nature of Transaction</th><th>FY 24-25 (₹ in million)</th></tr> <tr> <td>1</td><td>Sale of Goods</td><td>5</td></tr> <tr> <td>2</td><td>Purchase of Goods</td><td>588</td></tr> </table>	Sr. No.	Nature of Transaction	FY 24-25 (₹ in million)	1	Sale of Goods	5	2	Purchase of Goods	588
Sr. No.	Nature of Transaction	FY 24-25 (₹ in million)									
1	Sale of Goods	5									
2	Purchase of Goods	588									
2	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.	<table> <tr> <th>Sr. No.</th><th>Nature of Transaction</th><th>FY 25-26 (₹ in million)</th></tr> <tr> <td>1</td><td>Sale of Goods</td><td>4</td></tr> <tr> <td>2</td><td>Purchase of Goods</td><td>721</td></tr> </table>	Sr. No.	Nature of Transaction	FY 25-26 (₹ in million)	1	Sale of Goods	4	2	Purchase of Goods	721
Sr. No.	Nature of Transaction	FY 25-26 (₹ in million)									
1	Sale of Goods	4									
2	Purchase of Goods	721									
3	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last financial year	NIL									

A4 - Amount of the proposed transaction(s)

S. No.	Particulars of Information	Information provided by the management									
1	Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders	<table> <tr> <th>Sr. No.</th><th>Nature of Transaction</th><th>Amount of the proposed transaction (₹ in million)</th></tr> <tr> <td>1</td><td>Sale of Goods</td><td>50</td></tr> <tr> <td>2</td><td>Purchase of Goods</td><td>950</td></tr> </table>	Sr. No.	Nature of Transaction	Amount of the proposed transaction (₹ in million)	1	Sale of Goods	50	2	Purchase of Goods	950
Sr. No.	Nature of Transaction	Amount of the proposed transaction (₹ in million)									
1	Sale of Goods	50									
2	Purchase of Goods	950									
2	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes as the amount of the proposed transaction exceeds 10% of the annual consolidated turnover of AETL for FY 2026.									

3	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	<table><tr><th>Sr. No.</th><th>Nature of Transaction</th><th>Value of proposed RPT as a % of Company's annual consolidated turnover of FY 2026</th></tr><tr><td>1</td><td>Sale of Goods</td><td>0.7</td></tr><tr><td>2</td><td>Purchase of Goods</td><td>13</td></tr></table>	Sr. No.	Nature of Transaction	Value of proposed RPT as a % of Company's annual consolidated turnover of FY 2026	1	Sale of Goods	0.7	2	Purchase of Goods	13	
Sr. No.	Nature of Transaction	Value of proposed RPT as a % of Company's annual consolidated turnover of FY 2026										
1	Sale of Goods	0.7										
2	Purchase of Goods	13										
4	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary and where the listed entity is not a party to the transaction)	Not Applicable as the Company is a party to the transaction.										
5	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available	<table><tr><th>Sr. No.</th><th>Nature of Transaction</th><th>Value of proposed RPT as a % of JCB's annual Standalone turnover of FY 2026</th></tr><tr><td>1</td><td>Sale of Goods</td><td>7</td></tr><tr><td>2</td><td>Purchase of Goods</td><td>130</td></tr></table>	Sr. No.	Nature of Transaction	Value of proposed RPT as a % of JCB's annual Standalone turnover of FY 2026	1	Sale of Goods	7	2	Purchase of Goods	130	
Sr. No.	Nature of Transaction	Value of proposed RPT as a % of JCB's annual Standalone turnover of FY 2026										
1	Sale of Goods	7										
2	Purchase of Goods	130										
6	Financial performance of the related party for the immediately preceding financial year	<table><tr><th></th><th>FY 25-26 (₹ in million)</th></tr><tr><td>Particulars</td><td>JCB</td></tr><tr><td>Turnover</td><td>728</td></tr><tr><td>Profit after Tax</td><td>29</td></tr><tr><td>Net worth</td><td>662</td></tr></table>		FY 25-26 (₹ in million)	Particulars	JCB	Turnover	728	Profit after Tax	29	Net worth	662
	FY 25-26 (₹ in million)											
Particulars	JCB											
Turnover	728											
Profit after Tax	29											
Net worth	662											

A5 - Basic details of the proposed transactions

S. No.	Particulars of Information	Information provided by the management		
1	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Sr. No.	Nature of Transaction	Amount of the proposed transaction (₹ in million)
		1	Sale of Goods	50
		2	Purchase of Goods	950
2	Details of each type of the proposed transaction	1) Sale of various goods manufactured by the Company. Maximum value per invoice up to 10% of the aggregate limit in case of sales or ₹ 1 crore, whichever is more. 2) Purchase of various goods manufactured by JCB. Maximum value per purchase order up to 10% of the aggregate limit in case of purchase or ₹ 1 crore, whichever is more.		
3	Tenure of the proposed transaction (tenure in number of years or months to be specified)	From the date of ensuing 37 th Annual General Meeting (AGM) till the date of 38 th AGM		
4	Whether omnibus approval is being sought?	Yes		
5	Value of the proposed transaction during a financial year. If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Sr. No.	Nature of Transaction	Amount of the proposed transaction (₹ in million)
		1	Sale of Goods	50
		2	Purchase of Goods	950
		The tenure of the aforesaid proposed transactions is from the date of the 37 th AGM till the date of next AGM. A financial year -wise bifurcation of the aforesaid transactions was not estimated, as its dependent of various factors at the time of transaction / market conditions		

6	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	The transactions with JCB (sales/purchase) are of repetitive nature and in the ordinary course of business. The transactions with subsidiaries are based on various considerations including synergy in operations, overall business interest of the Company on consolidated basis, respective product specialization of the subsidiary, business model of the subsidiary, liquidity and to align and utilize the resources of the subsidiary
7	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly.	As mentioned below in 7(a)
a	Name of the director / KMP	Mr. Mukund Kabra, Whole-time Director (KMP) and Mr. Beni P Rauka, Chief Financial Officer (KMP) of the Company are the Directors on the Board of JCB, i.e. as Nominees representing the interest of the Company. Mr. Pramod Kasat is the common Independent Director
b	Shareholding of the director / KMP, whether direct or indirect, in the related party	NIL
8	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee	Not Applicable
9	Other information relevant for decision making	The said transaction of sales/purchase of goods with JCB is in the Ordinary Course of business and generally at arm's length basis as per the basis considered by the Board, however there may be a few transactions, which may be done in the interest of the Company.

The figures mentioned above have been rounded off, wherever applicable

B 1 - Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances

Part B – Additional Information

S. No.	Particulars of Information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services	The proposed transactions with the Related Party is to be carried out as part of the business requirements of the Company (i.e. in Ordinary course of business) and in the interest of the Company. The transactions with JCB (sales/purchase) are of repetitive nature and in the ordinary course of business. Such transactions are based on various considerations including synergy in operations, overall business interest of the Company on consolidated basis, respective product / research service specialization of the subsidiary, business model of the respective subsidiary, liquidity and to align and utilize the resources of the subsidiaries. The pricing of the products to be based on the current price charged and the Transfer Price Range read with other terms of the Transfer Pricing Policy of the Company
2	Basis of determination of price.	
3	In case of Trade advance (of up to 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	
a	Amount of Trade Advance	Not Applicable
b	Tenure	
c	Whether same is self-liquidating?	

As per the applicable provisions of the Act and SEBI Listing Regulations, no Related Parties shall vote to approve such resolution pertaining to the material related party transactions, whether the entity is a related party to the said transaction or not.

Further, the Audit Committee of the Board has received the Certificate provided by Chief Financial Officer and Whole-time Director confirming that the terms of the proposed Related Party transactions are in the interest of the Company.

The Board of Directors of the Company ("**Board**"), based on the recommendations of the Audit Committee, approved the said Related Party transactions with JCB, subject to the approval of the Members of the Company. The Board recommends the resolution set out at Item No. 8 to be passed as an **Ordinary Resolution**.

None of the Directors or Key Managerial Personnel of the Company or their Relatives are concerned or interested financially or otherwise in the resolution, except as mentioned above.

By Order of the Board of Directors

Sanjay Basantani

Company Secretary and Head – Legal

Membership No.: A19637

Place: Thane

Date: July 04, 2026

Registered Office:

Sun Magnetica, 'A' Wing

5th Floor, LIC Service Road, Louiswadi,

Thane (W) - 400 604, Maharashtra, India

Information on Director being appointed/re-appointed as required under Regulation 36 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-2 on General Meetings:

Name of Director	Ms. Rasika Rathi (DIN – 08300682)	Mr. Mukund Madhusudan Kabra (DIN – 00148294)	Mr. Pradip Bhailal Shah (DIN - 01225582)
Age	43 years	53 years	72 years
Experience/ Expertise in Specific Functional Area (including brief resume)	Ms. Rasika Rathi has over 21 years of rich experience in the field of Law and Enzymes and is associated as Vice President, General Counsel and Secretary at US subsidiary and Director of the European subsidiary. She is also associated as Director of the few subsidiaries of the Company in US. She was, in past, associated with Allen & Overy LLP in New York USA as an Associate – Tax and Litigation. She has founded a Non-profit National Information Centre in California USA to disseminate information about pulmonary fibrosis, conduct research and search for alternative therapies	Mr. Mukund Kabra, Whole-time Director of the Company, has around 31 years of experience in the enzyme industry and has been associated with the Company since 1995. Mr. Kabra is responsible for overlooking the manufacturing operations of the Company and for optimising the fermentation for existing products, strain improvement, downstream and analytical research. He has also been nominated on the Board of various subsidiaries of the Company	Mr. Pradip Shah is a veteran entrepreneur, operator, and investor with four decades of experience in building and leading businesses in the United States. He is a co-founder and Chief Executive Officer of Washington Garment Dyeing & Finishing, Inc. ("WGDF") and has also served as Vice –President of WGDF. He has also served as a Director on the Board of the Company from 1993 till 2016. His areas of expertise among others include financial operations and control, cross border investment, working capital and cash flow management, founder CEO leadership and real estate ownership and management.
Terms and Conditions of Appointment/ Reappointment	Re-appointment, as liable to retire by rotation	Refer to the explanatory statement pertaining to Item No. 5	Refer to the explanatory statement pertaining to Item No. 6
Details of Remuneration last drawn	Details of Commission paid/payable by the Company for the financial year 2025-26 is provided in Corporate Governance report, which forms part of the Integrated Annual report 2025-26, available on the website of the Company. Based on the approval of the Shareholders of the Company in its meeting held on July 15, 2020, she is also paid remuneration from US subsidiary, which was ₹ 22.08 million for FY 26.	Details of the last drawn remuneration is provided in the Corporate Governance report which forms part of the Integrated Annual Report of 2025-26 of the Company, available on the website of the Company (Refer to the explanatory statement pertaining to Item No. 5)	NIL
Details of remuneration sought to be paid	As may be decided by the Board Based on the approval of the Shareholders of the Company in its meeting held on July 15, 2020.	Refer to the explanatory statement pertaining to Item No. 5	Refer to the explanatory statement pertaining to Item No. 6
Date of First Appointment	January 08, 2019	September 04, 1999	June 12, 2026
Qualification	B.A. Economics from University of California, Berkeley, Juris Doctorate in Law from University of Michigan	Bachelor's degree in Chemical Engineering.	Bachelor of Commerce from Gujarat University and Advanced coursework in Management, Auditing, and Taxation from USA.
Shareholding in the Company (As on March 31, 2026)	26,65,825 Equity Shares (2.38 %)	18,26,750 Equity Shares (1.63 %)	18,57,400 Equity Shares (1.66 %)
No. of Board Meeting attended during the Financial Year	Eligible – Four Attended – Four	Eligible – Four Attended – Four	NA

Name of Director	Ms. Rasika Rath (DIN – 08300682)	Mr. Mukund Madhusudan Kabra (DIN – 00148294)	Mr. Pradip Bhailal Shah (DIN - 01225582)
Relative of any other Director / Manager and other KMP	Ms. Rasika Rath is Relative of Mr. Vasant Rath, Chairman of the Company	NIL	NIL
List of outside Directorship held	1) SciTech Specialities Private Limited 2) Advanced Enzymes Europe B. V. 3) Enzyme Innovation, Inc. 4) Advanced Supplementary Technologies Corporation 5) Starya Labs Inc. (The above are Subsidiaries/wholly-owned Subsidiaries of the Company)	1) Advanced Bio-Agro Tech Limited 2) Advanced Enzytech Solutions Limited 3) JC Biotech Private Limited 4) SciTech Specialities Private Limited 5) Saiganesh Enzytech Solutions Private Limited 6) Advanced Enzymes Europe B.V. 7) evovx Technologies GmbH (The above are Subsidiaries/wholly-owned Subsidiaries of the Company)	1) Advanced Enzymes, USA (wholly owned subsidiary of the Company) 2) Washington Garment Dyeing & Finishing, Inc.
Listed entities in which the person also holds the directorship and the membership of Committees of such Board along with listed entities from which the person has resigned in the past three years	NIL	NIL	NIL
Chairman / Member of the Committee of the Board of Directors of Other Companies	NIL	Member of Audit Committee, Nomination and Remuneration Committee and Corporate Social Responsibility (CSR) Committee of JC Biotech Private Limited. Member of Corporate Social Responsibility Committee of Advanced Bio-Agro Tech Limited (Subsidiaries of the Company)	NIL
In case of Independent director, the skills and capabilities required for the role and the manner in which the proposed person meets such requirements	Not Applicable	Not Applicable	Refer to the explanatory statement pertaining to Item No. 6

Note for the Members of Advanced Enzyme Technologies Limited ("Company") on Tax Deduction at Source on Dividend:

In accordance with the provisions of the Income-tax Act, 2025 as amended from time to time ("Act"), the final Dividend, if approved by the Members at the upcoming AGM is taxable in the hands of the Shareholders at the applicable rates.

1. To enable the Company to determine the appropriate TDS rate as may be applicable, Members are requested to submit the following document(s) and details, as applicable, by email to the Company at tds.dividend@advancedenzymes.com **on or before Monday, July 20, 2026**.

- a) **In case of Resident Individual Members:** TDS on Dividend under the provisions of Section 393 (1), (2) and (4) of the IT Act (or as may be amended / notified by the Government of India, from time to time):

- **TDS at 10%** on the Dividend amount, for Members having valid PAN registered in their respective folio/demat account.
- **TDS at 20%** - where Member(s) do not have PAN/Invalid PAN/have not provided or registered their PAN details in their respective folio/demat account / not linked their Aadhaar to the PAN.
- No tax is required to be deducted on the Dividend amount payable to a resident individual Member(s) if the total Dividend to be received by such Member(s) during tax year 2026-27 does not exceed ₹10,000; or in cases where Member(s) provides Form 121 (for individuals, with no tax liability on total income and income not exceeding maximum amount which is not chargeable to tax) / (for individual above the age of 60 years with no tax liability on total income) subject to the fulfilment of the conditions as may be specified in the IT Act, from time to time. The Member(s) may also submit any other document(s) as prescribed under the IT Act to claim a lower or NIL tax. Valid PAN is mandatory for Members providing Form 121 or any other document(s) as mentioned herein. Kindly take note that all the fields are mandatorily required to be duly filled in the aforementioned form 121, and the Company reserves the right to reject the Form that does not comply with applicable requirements.

- b) **In case of Resident Non-Individual Members:**

- **Insurance Companies:** For Public and other Insurance companies, a declaration that it has full beneficial interest with respect to the shares owned by it, along with self-attested copy of PAN;

- **Mutual Funds:** Self-declaration that it is registered with Securities and Exchange Board of India ('SEBI') and is notified under Section 11 of Schedule VII [Table Sr. No. 20] of the Act along with self-attested copy of PAN card and certificate of registration with SEBI;
 - **Alternative Investment Fund ("AIF"):** AIF established/incorporated in India - Self-declaration that its income is exempt under Section 393 (1) of the IT Act and they are governed by SEBI regulations as Category I or Category II AIF along with self-attested copy of the PAN card and SEBI registration certificate;
 - **Other Non-Individual Members:** Documentary evidence along with an attested copy of the PAN who are exempted from deduction of tax under Section 393 of the IT Act and categories who are covered under Section 196 of the IT Act.
- c) In case where the Members provide certificate under Section 395 of the IT Act for lower / NIL withholding of taxes, rate specified in the said certificate shall be considered based on submission of self-attested copy of the same.
 - d) **In case of Non-Resident Member(s):** Taxes are required to be withheld pursuant to the provisions of Section 393(2) and other applicable provisions of the IT Act, as per the rates applicable, from time to time. The withholding tax rate on the amount of Dividend payable shall be 20% plus applicable surcharge and cess, or as may be notified by the Government of India, from time to time. As per the IT Act, non-resident Members have the option to be governed by the provisions of the Double Tax Avoidance Agreement ("DTAA") between India and the country of tax residence of the said Member(s). The non-resident Member(s) shall provide the following document(s) to avail the available benefits under the provisions of DTAA:
 - i) Copy of the PAN card allotted by the authorities in India (duly certified by the Member) or details prescribed under Rule 217(2) of the Income Tax Rules.
 - ii) Copy of current year valid Tax Residency Certificate (TRC) obtained from the revenue authorities of the country of tax residence (duly certified by the Member)
 - iii) Electronically generated Form 41 from Income Tax portal
 - iv) Self-declaration by the Member(s) for having no permanent establishment in India in accordance with the applicable tax treaty

- v) Self-declaration of beneficial ownership by the Member(s)
- vi) Any other document(s) as may be prescribed under the provisions of the IT Act and/or required by the Company thereto, for lower withholding of taxes if applicable (duly certified by the Member)
- vii) If the Member is a tax resident of Singapore, in addition to the aforementioned (if applicable), kindly provide the letter from the relevant authority or any other documentary proof that Article 24 –Limitation of relief under India-Singapore Double Taxation Avoidance Agreement (DTAA) does not apply.

In case of Foreign Institutional Investors / Foreign Portfolio Investors: Tax will be deducted under the provisions of Section 393(2) of the IT Act at the rate of 20% plus applicable surcharge and cess or the rate provided in DTAA whichever is more beneficial, subject to the submission of above documents.

2. The cases where the dividend income is assessable to tax in the hands of a person other than the registered Member(s) as on the Record Date, the registered Member is required to furnish a declaration containing the name, address, PAN of the person to whom TDS credit is to be given and reasons for giving credit to such person.
3. The relevant forms and declarations as mentioned above can be downloaded from the website of the Company, under the tab "Note on TDS on Dividend" at www.advancedenzymes.com/investors/announcements-notices/. You are requested to provide all the requisite documents and details to tds.dividend@advancedenzymes.com on or before Monday, July 20, 2026 to enable the Company to determine the TDS/withholding tax rate on the dividend amount. No communication on the tax rate, tax deduction / determination shall be entertained by the Company after Monday, July 20, 2026.
4. Application of TDS rate is subject to necessary due diligence including verification by the Company of the details of the Member(s) available as per the Register of Members on the Record Date mentioned

in the AGM Notice, documents / other information available in the records of the Company / its Registrar to an Issue & Share Transfer Agent (RTA) and other reliable source(s). The Company may deduct TDS on Dividend (if approved at the AGM) at the maximum applicable rate, in case of any incomplete, conflicting or ambiguous information and/or the valid proper documents and/or information not provided by the Member(s).

5. In the event of any income tax demand(s) including any interest / penalty thereto etc. arising due to any misrepresentation, inaccuracy and/or omission of document(s) and/or information provided and/or to be provided by the Member(s), such Member(s) shall indemnify the Company and provide the Company with all the relevant information, documents and co-operation in any such proceedings.
6. In case TDS is deducted at a higher rate, an option would be available with the Member(s), as may be eligible subject to the applicable provisions, to file the return of income and claim an appropriate refund. No claim shall lie against the Company for such taxes deducted. Shareholders will be able to see the credit of TDS in Form 26AS, wherever PAN is available, which can be downloaded from their e-filing account at <https://eportal.incometax.gov.in/iec/fooservices> (or any other website as may be notified by the Authority).
7. The Resident Non-Individual Members i.e. Insurance companies, Mutual Funds and Alternative Investment Fund (AIF) established in India and Non-Resident Non-Individual Members i.e., Foreign Institutional Investors and Foreign Portfolio Investors may alternatively submit the relevant forms / declarations / documents through their respective custodian who is registered on NSDL platform, on or before the aforesaid timelines.
8. Apart from the above, since the TDS / Withholding rates are different for resident and non-resident shareholders, you are requested to update your Residential Status with your Registrar to an Issue and Share Transfer Agent / Depository Participant, which will be considered for determining tax rates as per the provisions for Income Tax Act 2025 (as amended from time to time).

Disclaimer:

The Notes on TDS as mentioned herein, set out the summary of applicable material provisions in India pertaining to TDS on the dividend payment by the company, and is subject to amendment(s), if any, from time to time and does not purport to be a complete and/or detailed analysis or listing of all potential tax consequences and/or applicability. The Members should consult their own tax advisor, as may be required, for the tax provisions applicability to them.
